Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARTIN I BELKIN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1861462129
CMS profile
130106
Location
FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$58,409.93

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Biogen, Inc. $14,815.32 13
EMD Serono, Inc. $13,069.80 11
GENZYME CORPORATION $9,291.94 6
Alexion Pharmaceuticals, Inc. $7,065.02 8
Genentech USA, Inc. $3,689.94 3
Celgene Corporation $3,362.07 5
E.R. Squibb & Sons, L.L.C. $3,212.18 2
TG THERAPEUTICS, INC. $1,940.00 1
Allergan, Inc. $1,750.00 1
Biohaven Pharmaceuticals, Inc. $81.41 4
Amgen Inc. $60.09 3
Novartis Pharmaceuticals Corporation $59.56 1
Zogenix Inc. $12.60 1

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARTIN I BELKIN

NPI 1861462129 · CMS profile ID 130106

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FARMINGTON HILLS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861462129?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARTIN I BELKIN, NPI 1861462129, CMS profile ID 130106. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861462129?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MARTIN I BELKIN, NPI 1861462129, CMS profile ID 130106. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861462129?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MARTIN I BELKIN, NPI 1861462129, CMS profile ID 130106, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1861462129?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $58,409.93 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $1,400.0003/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849179993 CMS
Alexion Pharmaceuticals, Inc. $945.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783118779 CMS
Alexion Pharmaceuticals, Inc. $840.0003/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783118783 CMS
Biogen, Inc. $1,077.0003/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827846977 CMS
Biohaven Pharmaceuticals, Inc. $20.8603/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852423503 CMS
Amgen Inc. $19.6402/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825592907 CMS
Celgene Corporation $1,200.0002/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783689479 CMS
Amgen Inc. $20.8701/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825592903 CMS
Allergan, Inc. $1,750.0001/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792704629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $125,752.20 296
PY2020 $72,001.09 112
PY2021 $58,409.93 59
PY2022 $96,884.32 136
PY2023 $125,218.10 192
PY2024 $131,967.26 150
PY2025 $101,459.89 77

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $321,587.18 82
PY2024 Principal investigator $322,354.60 142
PY2023 Principal investigator $395,011.58 122
PY2022 Principal investigator $205,433.60 118
PY2021 Principal investigator $452,816.88 139
PY2020 Principal investigator $1,538,582.79 119
PY2019 Principal investigator $1,814,625.25 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

82 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $257.00 12/19/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611033
Principal investigator 1 TG Therapeutics, Inc. $6,699.00 12/09/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200003
Principal investigator 1 GENZYME CORPORATION $120.00 12/02/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094483
Principal investigator 1 GENZYME CORPORATION $212.00 12/02/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094488
Principal investigator 1 GENZYME CORPORATION $397.00 12/02/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094494
Principal investigator 1 TG Therapeutics, Inc. $45.00 11/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200009
Principal investigator 1 F. Hoffmann-La Roche AG $81.00 11/19/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611037
Principal investigator 1 GENZYME CORPORATION $10,874.00 11/10/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094469
Principal investigator 1 GENZYME CORPORATION $9,677.00 11/10/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094476
Principal investigator 1 Genentech, Inc. $21,253.00 11/06/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625290
Principal investigator 1 Novartis Pharmaceuticals Corporation $260.00 11/01/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICAL DISORDERS
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190313873
Principal investigator 1 TG Therapeutics, Inc. $8,165.52 11/01/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200001
Principal investigator 1 Genentech, Inc. $34.00 10/27/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625286
Principal investigator 1 TG Therapeutics, Inc. $490.00 10/17/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200007
Principal investigator 1 Genentech, Inc. $3,834.00 10/08/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625281
Principal investigator 1 TG Therapeutics, Inc. $45.00 10/03/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200005
Principal investigator 1 GENZYME CORPORATION $3,126.00 09/29/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094465
Principal investigator 1 Genentech, Inc. $16,940.00 09/19/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625276
Principal investigator 1 Genentech, Inc. $6,144.00 09/18/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625283
Principal investigator 1 GENZYME CORPORATION $11,903.50 09/03/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094457
Principal investigator 1 TG Therapeutics, Inc. $2,721.84 08/31/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199961
Principal investigator 1 TG Therapeutics, Inc. $330.00 08/22/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199969
Principal investigator 1 TG Therapeutics, Inc. $9,007.40 07/31/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199959
Principal investigator 1 Genentech, Inc. $11.00 07/29/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625273
Principal investigator 1 GENZYME CORPORATION $5,287.00 07/28/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094446
Principal investigator 1 GENZYME CORPORATION $3,126.00 07/28/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094452
Principal investigator 1 TG Therapeutics, Inc. $490.00 07/25/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199967
Principal investigator 1 TG Therapeutics, Inc. $330.00 07/18/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199965
Principal investigator 1 TG Therapeutics, Inc. $200.00 07/11/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199963
Principal investigator 1 TG Therapeutics, Inc. $2,401.74 07/08/2025 Non-covered Recipient Entity
MIND
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200077
Principal investigator 1 GENZYME CORPORATION $10,661.00 07/02/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094439
Principal investigator 1 Genentech, Inc. $86.00 06/10/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625258
Principal investigator 1 TG Therapeutics, Inc. $20,098.68 06/01/2025 Non-covered Recipient Entity
MIND Clinic
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200357
Principal investigator 1 TG Therapeutics, Inc. $330.00 05/23/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199929
Principal investigator 1 GENZYME CORPORATION $11,026.00 05/19/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094433
Principal investigator 1 TG Therapeutics, Inc. $400.00 05/09/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199927
Principal investigator 1 TG Therapeutics, Inc. $445.00 05/02/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199925
Principal investigator 1 GENZYME CORPORATION $60.00 04/28/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226094344
Principal investigator 1 GENZYME CORPORATION $8,300.00 04/28/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094348
Principal investigator 1 GENZYME CORPORATION $200.00 04/28/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094356
Principal investigator 1 GENZYME CORPORATION $40.00 04/28/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094365
Principal investigator 1 TG Therapeutics, Inc. $500.00 04/25/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199923
Principal investigator 1 TG Therapeutics, Inc. $645.00 04/18/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199921
Principal investigator 1 Genentech, Inc. $4,764.00 04/15/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625266
Principal investigator 1 GENZYME CORPORATION $14,590.40 04/14/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094339
Principal investigator 1 TG Therapeutics, Inc. $45.00 04/11/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199919
Principal investigator 1 TG Therapeutics, Inc. $2,445.00 04/04/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199917
Principal investigator 1 Genentech, Inc. $34.00 04/02/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625269
Principal investigator 1 TG Therapeutics, Inc. $8,655.00 03/31/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199905
Principal investigator 1 F. Hoffmann-La Roche AG $2,839.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211610990
Principal investigator 1 F. Hoffmann-La Roche AG $7,340.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211610996
Principal investigator 1 F. Hoffmann-La Roche AG $3,042.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211610999
Principal investigator 1 F. Hoffmann-La Roche AG $257.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611003
Principal investigator 1 F. Hoffmann-La Roche AG $3,042.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611008
Principal investigator 1 F. Hoffmann-La Roche AG $2,839.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611012
Principal investigator 1 F. Hoffmann-La Roche AG $3,042.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611016
Principal investigator 1 F. Hoffmann-La Roche AG $2,839.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611020
Principal investigator 1 F. Hoffmann-La Roche AG $2,839.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611025
Principal investigator 1 F. Hoffmann-La Roche AG $5,981.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE No dispute reported 06/30/2026 1211611029
Principal investigator 1 TG Therapeutics, Inc. $130.00 03/21/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199915
Principal investigator 1 GENZYME CORPORATION $3,491.00 03/10/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094277
Principal investigator 1 GENZYME CORPORATION $30.00 03/04/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226094254
Principal investigator 1 GENZYME CORPORATION $30.00 03/04/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226094259
Principal investigator 1 GENZYME CORPORATION $180.00 03/04/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094265
Principal investigator 1 GENZYME CORPORATION $540.00 03/04/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094271
Principal investigator 1 GENZYME CORPORATION $90.00 03/04/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226094297
Principal investigator 1 TG Therapeutics, Inc. $2,290.00 02/28/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199903
Principal investigator 1 TG Therapeutics, Inc. $130.00 02/28/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199913
Principal investigator 1 TG Therapeutics, Inc. $5,337.20 02/26/2025 Non-covered Recipient Entity
MIND
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226200041
Principal investigator 1 GENZYME CORPORATION $864.50 02/18/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094291
Principal investigator 1 GENZYME CORPORATION $11,464.40 02/10/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094283
Principal investigator 1 GENZYME CORPORATION $75.00 02/10/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094308
Principal investigator 1 GENZYME CORPORATION $125.00 02/10/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226094315
Principal investigator 1 TG Therapeutics, Inc. $13,660.00 01/31/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199901
Principal investigator 1 TG Therapeutics, Inc. $2,335.00 01/31/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199911
Principal investigator 1 Genentech, Inc. $51.00 01/28/2025 Non-covered Recipient Entity
MICHIGAN INSTITUTE FOR NEUROLOGICA DISORDERS GLENDALE NEUROLOGICAL ASSOCIATES
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211625261
Principal investigator 1 TG Therapeutics, Inc. $130.00 01/24/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199909
Principal investigator 1 GENZYME CORPORATION $11,816.00 01/13/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094302
Principal investigator 1 GENZYME CORPORATION $12,516.00 01/13/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094320
Principal investigator 1 GENZYME CORPORATION $5,553.00 01/13/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094326
Principal investigator 1 GENZYME CORPORATION $8,857.00 01/13/2025 Non-covered Recipient Entity
Glendale Neurological Associates Pc
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226094332
Principal investigator 1 TG Therapeutics, Inc. $45.00 01/10/2025 Non-covered Recipient Entity
GLENDALE NEUROLOGICAL ASSOCIATES
(ENHANCE) Evaluating the maintenance of efficacy when transitioning from current anti-CD20 therapy to ublituximab No dispute reported 06/30/2026 1226199907